LEHI, Utah–(BUSINESS WIRE)–$owlt #babymonitor–Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the pricing of an underwritten public offering of 4,196,000 shares of the Company’s Class A common stock (the “Offering”). The shares of Class A common stock are being sold at a public offering price of $7.15 … [Read more…]
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage Program Takeda to Lead IBI363 Global Co-Development and U.S. Co-Commercialization and Will Have Exclusive Commercialization Rights Outside the U.S. and Greater China; IBI363 is a Late-Stage Bispecific Antibody Fusion … [Read more…]
WASHINGTON–(BUSINESS WIRE)–A network of over 30 rural and urban nonprofit safety net providers appealed to congressional leaders to protect the 340B Drug Pricing Program, highlighting how the program enables the high-quality care they provide to medically underserved Americans. The 340B Rural Advocacy Network released the letter prior to a U.S. Senate Health Education Labor and … [Read more…]
FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern … [Read more…]
A Global Turning Point for Critical Care Medicine TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the world’s only recombinant apoA-I, today announced the publication of a ground breaking study in Scientific Reports in Nature Portfolio titled “Plasma apolipoprotein A-I is a … [Read more…]
BALTIMORE–(BUSINESS WIRE)–Medifast (NYSE: MED), the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended September 30, 2025 on Monday, November 3, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company … [Read more…]
Findings presented at IDWeek 2025 underscore the importance of considering serotypes that disproportionately impact adults in the U.S. and show greater resistance to commonly prescribed antibiotics RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a systematic literature review of studies … [Read more…]
Bayer to unveil latest details on study design and baseline characteristics of the Phase III OCEANIC-STROKE study with asundexian Investigational agent asundexian is a once-daily, oral Factor XIa (FXIa) inhibitor WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking … [Read more…]
(CUSIP NOS. 05151A AA1 / L0415A AA1) LUXEMBOURG–(BUSINESS WIRE)–Auna S.A. (NYSE: AUNA), a public limited liability company (société anonyme) incorporated and existing under the laws of Luxembourg, having its registered office at 6, rue Jean Monnet, L-2180 Luxembourg, and registered with the Luxembourg Trade and Companies Register (Registre de Commerce et des Sociétés, Luxembourg) under … [Read more…]
Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad range of cancers Collaboration will add a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis’ oncology portfolio Phrontline will be responsible for creating bispecific, dual-payload ADCs using its bispecific antibody and dual-linker payload … [Read more…]
